Groundbreaking research using Nucleome MCC technology reveals complex structure of DNA inside\r\nliving cells at base pair resolution for the first time, pioneering a new approach to identify new drug\r\ntargets from human genetics.
Enara Bio, a biopharmaceutical company pioneering the discovery of novel Dark Antigens\u00ae and the development of bispecific T cell engagers for solid tumours, will unveil its newly discovered cancer-specific target DARKFOX\u2122 as the first in a new category of validated Dark Antigens in an oral presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 annual meeting. SITC 2025 is being held on November 5-9 in National Harbor, MD.
The University of Liverpool rand CyanoCapture Ltd are joining forces to develop the next generation of carboxysome-based targeted drug delivery systems, exploiting unique traits found in fast-growing cyanobacteria.
Leveraging deep scientific and clinical expertise in MPNs, the company aims to drive a pipeline of disease-modifying precision therapies that selectively target disease-driving cells. Progress is being made with AT-01, a first-in-class antibody-drug conjugate (ADC) program, which has strong preclinical validation and is advancing toward IND/CTA-enabling studies anticipated to start in the first half of 2026. Additionally, AT-02 expands the ADC portfolio by targeting mutant CALR, a key driver mutation in MPNs. The leadership and board have been strengthened with the appointments of Dr. Rohit Batta as CEO and Mike Grey as Chair.
U-Ploid is today presenting its first scientific abstract, \u201cPreclinical testing of a novel therapeutic for reduction of aneuploidy in oocytes,\u201d at the 2025 American Society for Reproductive Medicine (ASRM) Annual Meeting in San Antonio, Texas. The study showcases preclinical data on Lyvanta\u2122 (UP-085), a novel therapeutic designed to reduce chromosome segregation errors in oocytes associated with maternal age.
MediMabBio has successfully raised KRW 25.6B (USD $17M) in its Series B financing round. The newly secured capital will be used to expand strategic global partnerships for accelerated business development and the advancement of follow-on programs.
MediMabBio won first place at Innovation Tiger 2025, a global biotech startup competition held at Shonan iPark in Japan. The final round featured 16 companies selected from 79 applicants across Korea, Japan, and Taiwan.
Dr. Peter Jianrui Liu, Co-Founder of OXcan, has decided to step down from his role as the Company\u2019s Founding CEO, to pursue other interests. He will remain a significant shareholder in the Company and therefore will retain every interest in the Company\u2019s development and success as an advisor.
We are delighted to welcome Professor Heidi Johansen-Berg to our Management Board, an expert in brain imaging and neuroplasticity, and a champion of innovation in the life sciences.
Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260. THEO-260, is currently being investigated in patients with platinum-resistant ovarian cancer.
53.7% mean splicing correction observed following a single 15 mg/kg dose of PGN-EDODM1, with all patients showing an improvement in splicing. PGN-EDODM1 was generally well-tolerated at 15 mg/kg, with drug-related adverse events mild or moderate in severity
PepGen currently intends to use the net proceeds from this offering to fund its ongoing research and clinical development efforts, including the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, as well as for working capital and other general corporate purposes.
In the piece, CEO and co-founder Dr. Peter Jianrui Liu shares how the company is pioneering a non-invasive blood test for the early detection of lung cancer, using proteomics and AI/ML. Oxford Cancer Analytics' technology aims to change the way cancers are diagnosed, detecting disease earlier, cutting costs for health systems, and most importantly, saving lives.
We are delighted to welcome Omos Biosciences as the newest member of the BioEscalator community. The company has ambitious plans to transform cancer prevention by intervening at the pre-cancerous stage.
Follows successful completion of pre-clinical activities by Alchemab as part of an earlier licensing deal with Eli Lilly and Company for ATLX-1282. Financing included participation from Eli Lilly and Company and Ono Venture Investment alongside significant support from world-class existing investors.
Collaboration leverages OMass\u2019 OdyssionTM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease. OMass to receive $20M upfront payment, with potential for more than $400M in additional milestone payments, as well as tiered royalties on net sales.
![\"\"](\"https://www.bioescalator.ox.ac.uk/news-and-events/news/nucleome-therapeutics-founder-professor-james-davies-and-oxford-university-publish-paper-in-prestigious-journal-cell/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n